Scientific Presentations and Publications

Presentations

February 2023: AAAAI Annual Meeting

Structure of STAR-0215 Bound to Active Plasma Kallikrein Reveals a Novel Mechanism of Enzyme Inhibition

February 2023: AAAAI Annual Meeting

Initial Results from a Phase 1a Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema, in Healthy Adult Subjects Followed for at Least 3 Months

November 2022: ACAAI Annual Scientific Meeting

Modeling and Simulation Predicts Robust HAE Attack Suppression with Every 3 Month Dosing of STAR-0215

July 2022: EAACI Annual Congress

STAR-0215, a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE, Demonstrates Sustained Functional Inhibition in Subcutaneously Dosed Cynomolgus Monkeys

July 2022: EAACI Annual Congress

STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE

April 2022: Fc Receptor and IgG Targeted Therapies Conference

Development of STAR-0215: PKPD Model of STAR-0215, an Engineered IgG1 Monoclonal Antibody Targeting Plasma Kallikrein for the Prevention of HAE

February 2022: AAAAI Annual Meeting

STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE

Nov. 2021: ACAAI Annual Scientific Meeting

STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for the Potential Treatment of HAE

Oct. 2021: NORD Summit

Burdens of Disease and Treatment in Hereditary Angioedema: Interview Insights from HAE Patients